Cart
sales@molnova.com
Risedronate Sodium
CAS No. 115436-72-1
Risedronate Sodium( —— )
Catalog No. M10542 CAS No. 115436-72-1
Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 28 | In Stock |
|
| 100MG | 37 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 68 | In Stock |
|
| 1G | 91 | In Stock |
|
Biological Information
-
Product NameRisedronate Sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionRisedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
-
DescriptionRisedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHAP| FPS
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number115436-72-1
-
Formula Weight305.09
-
Molecular FormulaC7H10NNaO7P2
-
Purity>98% (HPLC)
-
SolubilityWater: 2 mg/mL (6.55 mM)
-
SMILESO.O.O.O.O.[Na+].OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O.OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bergstrom JD, et al. Arch Biochem Biophys. 2000 Jan 1;373(1):231-4
molnova catalog
related products
-
Burfiralimab
Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
-
IR415
IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression.
-
BCM-599
BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
